论文部分内容阅读
目的探讨缬沙坦对高血压患者的胰岛素抵抗、hs-CRP的疗效。方法选择98例轻中度原发性高血压患者,随机分为两组,治疗组给予缬沙坦,80mg/d,对照组给予硝苯地平缓释片10mg,2次/d。疗程为12周。在治疗前后测定空腹hs-CRP、血糖、胰岛素水平,用HOMA-IR公式计算胰岛素抵抗指数,比较治疗前后hs-CRP、空腹胰岛素、HOMA-IR变化。结果两组患者治疗12周后,收缩压、舒张压均有显著下降,与治疗前比较其差异有统计学意义(P<0.01);缬沙坦组治疗后血清hs-CRP、空腹胰岛素水平、HOMA-IR明显降低,与治疗前比较其差异有统计学意义(P<0.05),对照组治疗后hs-CRP、空腹胰岛素水平、HOMA-IR与治疗前比较其差异无统计学意义(P>0.05)。缬沙坦组治疗后hs-CRP、空腹胰岛素水平、HOMA-IR水平与对照组治疗后比较其差异有统计学意义(P<0.05)。结论缬沙坦能有效控制血压,降低hs-CRP水平,改善胰岛素抵抗。
Objective To investigate the effect of valsartan on insulin resistance and hs-CRP in patients with hypertension. Methods A total of 98 patients with mild-to-moderate essential hypertension were randomly divided into two groups. The treatment group was given valsartan 80 mg / d, while the control group was given nifedipine 10 mg twice daily. Treatment for 12 weeks. The fasting hs-CRP, blood glucose and insulin levels were measured before and after treatment. The insulin resistance index was calculated by HOMA-IR formula. The changes of hs-CRP, fasting insulin and HOMA-IR before and after treatment were compared. Results After treatment for 12 weeks, the systolic and diastolic blood pressures decreased significantly in both groups (P <0.01). The levels of serum hs-CRP, fasting insulin, HOMA-IR was significantly lower than that before treatment (P <0.05). There was no significant difference in hs-CRP, fasting insulin and HOMA-IR between the two groups after treatment (P> 0.05). The difference of hs-CRP, fasting insulin and HOMA-IR between the valsartan group and the control group after treatment was statistically significant (P <0.05). Conclusion Valsartan can effectively control blood pressure, reduce hs-CRP level and improve insulin resistance.